- Coloplast’s first-quarter revenue was DKK 7.03 billion, close to the expected DKK 7.05 billion.
- The company’s EBITDA was DKK 2.24 billion, exceeding the forecast of DKK 2.16 billion.
- Earnings before interest and taxes (EBIT) reached DKK 1.84 billion.
- Net income stood at DKK 1.04 billion, which was below the estimated DKK 1.29 billion.
- Analysts’ recommendations included 13 buys, 11 holds, and 4 sells on Coloplast’s stock.
A look at Coloplast A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coloplast A/S, a company specializing in healthcare products, has a mixed outlook for the long term based on the Smartkarma Smart Scores. With a solid Dividend score of 4, investors can expect a stable return on their investment in Coloplast. However, the company’s Value and Resilience scores are on the lower side at 2, indicating that there may be some challenges in terms of the company’s valuation and ability to withstand economic uncertainties. On the positive side, Coloplast receives a Growth score of 3 and a Momentum score of 3, suggesting some potential for future expansion and market momentum.
In summary, Coloplast A/S is a healthcare company focusing on products for ostomy, incontinence, mastectomy, wound healing, and skin care. While it offers a promising Dividend score, other factors like Value and Resilience score lower. The Growth and Momentum scores provide some optimism for the company’s future prospects. Investors may want to consider these factors carefully when evaluating their long-term investment strategy in Coloplast A/S.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
